<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152889</url>
  </required_header>
  <id_info>
    <org_study_id>ZG IIIS</org_study_id>
    <nct_id>NCT04152889</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer</brief_title>
  <official_title>A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Camrelizumab in Combination With Docetaxel +S-1&#xD;
      Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer&#xD;
      (PD-L1 + / MSI-H / EBV +/dMMR) . Secondary study objective: To observe and evaluate the&#xD;
      overall survival and adverse events of Camrelizumab in Combination With Docetaxel +S-1&#xD;
      Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer&#xD;
      (PD-L1 + / MSI-H / EBV +/dMMR). To evaluate the safety ofCamrelizumab in Combination With&#xD;
      Docetaxel +S-1 Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III&#xD;
      Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR). Objective: To explore the incidence of PD-L1 +&#xD;
      / MSI-H / EBV + /dMMR in stage III gastric cancer. To explore the correlation of PD-L1 + /&#xD;
      MSI-H / EBV + /dMMR in stage III gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>1YEARS</time_frame>
    <description>disease-free survival</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastric Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Camrelizumab+chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.</description>
    <arm_group_label>Camrelizumab+chemotherapy</arm_group_label>
    <other_name>SHR-1210</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.</description>
    <arm_group_label>Camrelizumab+chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel: 40 mg/m^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.</description>
    <arm_group_label>Camrelizumab+chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patients voluntarily joined the study and signed the informed consent;&#xD;
&#xD;
          2. ≥ 18 years old, ≥ 80 years old, both male and female;&#xD;
&#xD;
          3. Stage III gastric cancer confirmed by pathology,&#xD;
&#xD;
          4. ECoG score: 0-1&#xD;
&#xD;
          5. Detection of biomarkers in postoperative gastric cancer samples suggests that: PD-L1 +&#xD;
             CPS ≥ 10% / MSI-H + / EBV+/dMMR&#xD;
&#xD;
          6. No preoperative anti-tumor treatment for gastric cancer, including chemotherapy and&#xD;
             local treatment&#xD;
&#xD;
          7. During the study treatment period and within 3 months after the end of the study&#xD;
             treatment period, a medically recognized contraceptive measure (such as IUD,&#xD;
             contraceptive pill or condom) should be used for the female patients of non-surgical&#xD;
             sterilization or childbearing age; the serum or urine HCG test of the female patients&#xD;
             of non-surgical sterilization must be negative within 72 hours before the study group;&#xD;
             and the hCG test must be non lactation; for the male patients Sex, should be surgical&#xD;
             sterilization, or agree to use appropriate methods of contraception during the trial&#xD;
             and within 3 months after the last administration of the test drug.&#xD;
&#xD;
          8. The baseline blood routine and biochemical indexes of the selected patients should&#xD;
             meet the following standards:&#xD;
&#xD;
        A. hemoglobin ≥ 90g / L&#xD;
&#xD;
        B. absolute neutrophil count ≥ 1.5 × 10 ^ 9 / L&#xD;
&#xD;
        C. platelet count ≥ 100 × 10 ^ 9 / L&#xD;
&#xD;
        D. ASTor ALT ≤ 2.5 ULN&#xD;
&#xD;
        E. Alkaline phosphatase (ALP)≤ 2.5×ULN&#xD;
&#xD;
        TSH ≤ 1 ULN (if abnormal, T3 and T4 levels should be examined at the same time, if T3 and&#xD;
        T4 levels are normal, they can be included in the group);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women;&#xD;
&#xD;
          2. Women of childbearing age were positive in the baseline pregnancy test;&#xD;
&#xD;
          3. Distant metastasis was diagnosed by CT /MR/ EUS.&#xD;
&#xD;
          4. Received previous anti-tumor treatment, including chemotherapy, radiotherapy or&#xD;
             immunotherapy;&#xD;
&#xD;
          5. Have other malignant tumors in the past 5 years (except basal cell or squamous cell&#xD;
             carcinoma, superficial bladder cancer, cervical cancer in situ or breast cancer);&#xD;
&#xD;
          6. Uncontrollable pleural effusion, pericardial effusion or ascites;&#xD;
&#xD;
          7. Severe cardiovascular diseases such as symptomatic coronary heart disease, congestive&#xD;
             heart failure ≥ level II, uncontrolled arrhythmia and myocardial infarction within 12&#xD;
             months before admission;&#xD;
&#xD;
          8. With gastroduodenal obstruction/bleeding, digestive dysfunction or malabsorption&#xD;
             syndrome&#xD;
&#xD;
          9. Complicated with severe uncontrolled concurrent infection or other serious&#xD;
             uncontrolled concomitant diseases, moderate or severe renal injury;&#xD;
&#xD;
         10. Allergic reaction to the drugs used in this study;&#xD;
&#xD;
         11. Steroid or other systemic immunosuppressive therapy was used 14 days before admission;&#xD;
&#xD;
         12. Patients who received study drug treatment within 4 weeks before enrollment&#xD;
             (participate in other clinical trials).&#xD;
&#xD;
         13. Active autoimmune diseases (including but not limited to: uveitis, enteritis,&#xD;
             hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, hypothyroidism and&#xD;
             asthma requiring bronchodilator treatment). Subjects with hypothyroidism requiring&#xD;
             only hormone replacement therapy and skin diseases without systemic treatment (such as&#xD;
             vitiligo, psoriasis or alopecia) can be selected.&#xD;
&#xD;
         14. History of primary immunodeficiency.&#xD;
&#xD;
         15. Immunosuppressive drugs were used within 4 weeks prior to the first dose of study&#xD;
             treatment, excluding local or physiological doses of systemic glucocorticoids (i.e. no&#xD;
             more than 10mg / day of prednisone or other glucocorticoids of equivalent dose) by&#xD;
             nasal spray, inhalation or other routes, or hormones used to prevent allergy of&#xD;
             contrast agents.&#xD;
&#xD;
         16. Receive live attenuated vaccine within 4 weeks before the first dose of study&#xD;
             treatment or during the study period.&#xD;
&#xD;
         17. Active tuberculosis is known.&#xD;
&#xD;
         18. We have known the history of allogeneic organ transplantation and allogeneic&#xD;
             hematopoietic stem cell transplantation.&#xD;
&#xD;
         19. HIV antibody positive, active hepatitis B or C (hepatitis B: HBsAg positive and HBV&#xD;
             DNA ≥ 10 ⁴ copies / ml; hepatitis C: HCV antibody and HCV-RNA positive, requiring&#xD;
             antiviral treatment at the same time);.&#xD;
&#xD;
         20. Other factors that may affect the safety or test compliance of the subjects according&#xD;
             to the judgment of the researchers. For example, serious diseases (including mental&#xD;
             diseases) requiring combined treatment, serious laboratory abnormalities, or other&#xD;
             family or social factors, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital, Shanghai JiaoTong University, School of Medicine Shanghai, Shanghai, China, 200127</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gang Zhao</last_name>
    <phone>0086-021-68383731</phone>
    <email>zhaogang74313@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Zhao</last_name>
      <phone>0086-021-68383731</phone>
      <email>zhaogang74313@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>zhaogang</investigator_full_name>
    <investigator_title>Deputy director of gastrointestinal surgery administration</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

